Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
European Innovation Council funding supports advancement of AT-108, Asgard’s first-in-class off-the-shelf cell reprogramming immunotherapy, toward First-in-Human clinical trialGrant opens the...